Preclinical studies form the cornerstone of drug development, providing critical data on feasibility and safety before human trials begin. Whilst regulatory bodies like FDA and EMA offer scientific guidelines for non-clinical testing, the selection of appropriate drug delivery systems remains unstandardised—yet plays a crucial role in study outcomes and translational success. Selecting the right delivery system can significantly impact bioavailability, dose consistency, and ultimately, the predictive value of your preclinical data. As researchers push the boundaries of respiratory therapeutics, understanding these delivery considerations becomes increasingly vital.
Join us as we explore optimal delivery strategies for pulmonary and nasal drug administration across various animal species, with special focus on small animal models. We’ll examine how anatomical differences between species affect deposition patterns and drug absorption, and discuss scaling approaches for translating findings to human applications. Our experts will present novel insufflator and micro sprayer technologies through illuminating case studies, demonstrating how these innovative platforms can enhance your preclinical programme design and overcome common technical challenges that have historically limited the predictive power of animal models.
<span>By ticking this box, you are accepting <a href=”https://aptar.com/general-terms-and-conditions-of-use/” style=”color:white; text-decoration: underline;” target=”_blank”>Aptar’s Privacy Policy and General Terms and Conditions</a> and consenting to have your information shared, for marketing purposes, possibly outside of the European Union.</span>